Gotta keep the board on their toes and good to see they came out quickly with the announcement.
On track for approval in the US of Remestemcel-L for treatment of SR-aGVHD in the US.
Importantly it will lift the profile of Mesoblast and the mechanism of action to treat cytokine release syndrome and further application of remestemcel for UNMET needs.
Large Pharma take notice.......sit tight
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L, page-18
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.065(4.66%) |
Mkt cap ! $1.667B | |||
| Open | High | Low | Value | Volume |
| $1.41 | $1.50 | $1.40 | $5.699M | 3.943M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 122380 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 11015 | 2 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |